Keeps Pharma to Attend BIO USA, Pursue Anticancer Drug and Oral Platform Technology Partnerships with Big Pharma View original image

Keeps Biopharma (Keeps Pharma) is set to expand its partnerships with global pharmaceutical companies by participating in the world’s largest biotechnology industry event, the BIO International Convention 2026 (BIO USA).


Keeps Pharma announced on June 9 that it will be taking part in BIO USA, which will be held in San Diego, United States, from June 22 to June 25.


In this event, its core subsidiaries will also participate: Algok Bio, the U.S. subsidiary focused on new drug development, and Keeps Biomed, which develops oral platform technologies. Both companies plan to pursue global commercialization and technology collaboration opportunities based on their respective core pipelines and platform technologies.


In particular, Algok Bio has finalized a schedule for face-to-face meetings with several global big pharma companies to discuss the technology transfer and joint development of its next-generation small molecule anticancer drug, "Idetrexed," which targets folate receptor alpha (FRα).


The company explained that global pharmaceutical firms are showing increasing interest in the early data and clinical progress of the phase 1b/2a clinical trials of Idetrexed in combination with a PARP inhibitor, which are currently being conducted in the United Kingdom.


Idetrexed has been recognized for overcoming the toxicity issues commonly associated with conventional antibody-drug conjugate (ADC) therapies, and is noted for its superior safety profile and potential to be combined with a variety of anticancer agents, setting it apart from existing treatments. The company stated that these factors are what have drawn the attention of global pharmaceutical companies.


Keeps Biomed, which is developing an oral peptide drug delivery platform, also plans to expand global partnering at this event. Building on its participation in last year’s BIO Europe in Austria, the company aims to showcase the competitiveness of its proprietary platform, "Oralloid," at BIO USA by highlighting its high absorption rate data.


In addition, the company will further outline its development roadmap for oral insulin and anti-obesity drugs (GLP-1), while also considering opportunities to enhance the platform’s competitiveness through additional technology in-licensing (License-In).


Keeps Pharma CEO Kim Hayong stated, "Participation in this year’s BIO USA is an important opportunity to directly validate the clinical value of Idetrexed and the technological prowess of the Oralloid platform in the global market," adding, "Through scheduled meetings with global big pharma companies, we aim to facilitate meaningful partnerships and technology transfer discussions."



Keeps Pharma’s participation in BIO USA is expected to serve as a catalyst for the company to actively expand its collaborations and technology transfer opportunities with global pharmaceutical companies, leveraging its anticancer drug and oral platform technologies.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing